You are here

Hospira Exchange Offer Tax Information

Disclosure Pursuant to U.S. Treasury Regulation Section 1.1273-2(f)(9)

On October 5, 2015, Pfizer Inc. (“Pfizer”) consummated exchange offers and consent solicitations with holders of Hospira, Inc. (“Hospira”) Notes pursuant to which, among other things: Pfizer (i) issued 6.05% Pfizer Notes due 2017 (the “6.05% Pfizer Notes”) in exchange for 6.05% Hospira Notes due 2017, (ii) issued 5.20% Pfizer Notes due 2020 (the “5.20% Pfizer Notes”) in exchange for 5.20% Hospira Notes due 2020, (iii) issued 5.80% Pfizer Notes due 2023 (the “5.80% Pfizer Notes”) in exchange for 5.80% Hospira Notes due 2023, and (iv) issued 5.60% Pfizer Notes due 2040 (the “5.60% Pfizer Notes” and, together with the 6.05% Pfizer Notes, the 5.20% Pfizer Notes and the 5.80% Pfizer Notes, the “Pfizer Notes”) in exchange for 5.60% Hospira Notes due 2040.

Pursuant to U.S. Treasury Regulation section 1.1273-2(f)(9) (the “Regulation”), Pfizer has made the following determinations with respect to the Pfizer Notes:

(i) the 6.05% Pfizer Notes (CUSIP Number 717081DQ3) are “traded on an established market” within the meaning of U.S. Treasury Regulations section 1.1273-2. The “issue price” of the 6.05% Pfizer Notes within the meaning of U.S. Treasury Regulations section 1.1273-2(b) is 107.055.

(ii) the 5.20% Pfizer Notes (CUSIP Number 717081DR1) are “traded on an established market” within the meaning of U.S. Treasury Regulations section 1.1273-2. The “issue price” of the 5.20% Pfizer Notes within the meaning of U.S. Treasury Regulations section 1.1273-2(b) is 113.365.

(iii) the 5.80% Pfizer Notes (CUSIP Number 717081DS9) are “traded on an established market” within the meaning of U.S. Treasury Regulations section 1.1273-2. The “issue price” of the 5.80% Pfizer Notes within the meaning of U.S. Treasury Regulations section 1.1273-2(b) is 115.890.

(iv) the 5.60% Pfizer Notes (CUSIP Number 717081DT7) are “traded on an established market” within the meaning of U.S. Treasury Regulations section 1.1273-2. The “issue price” of the 5.60% Pfizer Notes within the meaning of U.S. Treasury Regulations section 1.1273-2(b) is 114.010.

As provided by the Regulation, these determinations are binding upon all holders of the Pfizer Notes unless such holder explicitly discloses, in accordance with the requirements of the Regulation, that its determination is different from Pfizer's determination on the holder’s timely filed federal income tax return for the taxable year that includes its acquisition date of the Pfizer Notes.

This notice is only intended to fulfill Pfizer's notification obligation under the Regulation and does not constitute tax advice. Holders of the Pfizer Notes are encouraged to obtain independent tax advice to determine the implications of this notification to them.